BioSpace News Archive

Locanabio, Inc. today announced the appointment of Kat Lange as chief financial officer.

Isoprene Pharmaceuticals, Inc., an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer (TNBC) and other cancers, today announced that the National Institute of Health’s (NIH) NCI has awarded the company a two-year $2 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant.

Pear Therapeutics, Inc. today announced management’s participation in the Morgan Stanley 19th Annual Global Healthcare Conference.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic (inactive) TED.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and the nonprofit Institute for Life Changing Medicines (ILCM), today announced a new collaboration to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1x1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced two key executive appointments that bring industry-leading market growth and access experience to the company.

Viveve Medical, Inc. today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.